HK1213480A1 - 用於持續釋放蛋白質的生物可降解的藥物遞送系統 - Google Patents
用於持續釋放蛋白質的生物可降解的藥物遞送系統Info
- Publication number
- HK1213480A1 HK1213480A1 HK16101450.3A HK16101450A HK1213480A1 HK 1213480 A1 HK1213480 A1 HK 1213480A1 HK 16101450 A HK16101450 A HK 16101450A HK 1213480 A1 HK1213480 A1 HK 1213480A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- proteins
- drug delivery
- sustained release
- delivery systems
- biodegradable drug
- Prior art date
Links
- 238000012377 drug delivery Methods 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 238000013268 sustained release Methods 0.000 title 1
- 239000012730 sustained-release form Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
- A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Vascular Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Prostheses (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261706516P | 2012-09-27 | 2012-09-27 | |
PCT/US2013/061803 WO2014052518A1 (en) | 2012-09-27 | 2013-09-26 | Biodegradable drug delivery systems for the sustained release of proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1213480A1 true HK1213480A1 (zh) | 2016-07-08 |
Family
ID=49447799
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16101450.3A HK1213480A1 (zh) | 2012-09-27 | 2016-02-05 | 用於持續釋放蛋白質的生物可降解的藥物遞送系統 |
Country Status (13)
Country | Link |
---|---|
US (2) | US10653621B2 (zh) |
EP (1) | EP2900250B1 (zh) |
JP (1) | JP6317748B2 (zh) |
KR (2) | KR20200065106A (zh) |
CN (1) | CN104812397A (zh) |
AU (2) | AU2013323553B2 (zh) |
BR (1) | BR112015006929A2 (zh) |
CA (1) | CA2886081A1 (zh) |
ES (1) | ES2709351T3 (zh) |
HK (1) | HK1213480A1 (zh) |
RU (1) | RU2676102C2 (zh) |
TW (1) | TWI663985B (zh) |
WO (1) | WO2014052518A1 (zh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017192590A2 (en) * | 2016-05-02 | 2017-11-09 | The Regents Of The University Of Michigan | Coated implants for long-term controlled release of antibody therapeutics |
IL271908B2 (en) * | 2017-07-11 | 2024-02-01 | Sustained Nano Systems Llc | Over-compressed pharmaceutical preparations |
KR20200130392A (ko) * | 2018-03-09 | 2020-11-18 | 발리터 인코포레이티드 | 관절 염증의 지속적인 관절내 치료를 위한 다가 펩티드 컨쥬게이트 |
EP3801378A4 (en) | 2018-05-24 | 2022-02-23 | Celanese EVA Performance Polymers LLC | IMPLANTABLE DEVICE FOR THE DELAYED RELEASE OF A MACROMOLECULAR DRUG COMPOUND |
US11690807B2 (en) | 2018-05-24 | 2023-07-04 | Celanese Eva Performance Polymers Llc | Implantable device for sustained release of a macromolecular drug compound |
AU2019413436A1 (en) * | 2018-12-28 | 2021-07-01 | National Cheng Kung University | Biological scaffold and method for fabricating the same |
CN110051650A (zh) * | 2019-04-29 | 2019-07-26 | 南京锐利施生物技术有限公司 | 用于玻璃体注射的贝伐单抗和***共载的纳米粒药物 |
AU2020302924A1 (en) | 2019-06-27 | 2022-02-17 | Layerbio, Inc. | Ocular device delivery methods and systems |
GB202018889D0 (en) * | 2020-12-01 | 2021-01-13 | UCB Biopharma SRL | Formulations |
CN117203178A (zh) * | 2021-02-24 | 2023-12-08 | 治疗调适公司 | 陶瓷组合物和使用方法 |
GB202103785D0 (en) * | 2021-03-18 | 2021-05-05 | UCB Biopharma SRL | Formulations |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6309669B1 (en) | 1984-03-16 | 2001-10-30 | The United States Of America As Represented By The Secretary Of The Army | Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix |
US4853224A (en) | 1987-12-22 | 1989-08-01 | Visionex | Biodegradable ocular implants |
US4997652A (en) | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
US6448077B1 (en) | 1994-02-10 | 2002-09-10 | Imclone Systems, Inc. | Chimeric and humanized monoclonal antibodies specific to VEGF receptors |
US5869079A (en) * | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
US20020111603A1 (en) | 1996-12-02 | 2002-08-15 | Societe De Conseils De Recherches Et D'application | Device for local administration of solid or semi-solid formulations and delayed-release formulations for proposal parental administration and preparation process |
US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
IL155479A0 (en) | 2000-11-03 | 2003-11-23 | Control Delivery Sys Inc | Improved device and method for treating conditions of a joint |
CA2460587A1 (en) | 2001-09-20 | 2003-03-27 | Alexion Pharmaceuticals, Inc. | Anti-pdgf antibodies and methods for producing engineered antibodies |
US6899717B2 (en) | 2002-09-18 | 2005-05-31 | Allergan, Inc. | Methods and apparatus for delivery of ocular implants |
WO2004043432A2 (en) | 2002-11-06 | 2004-05-27 | Alza Corporation | Controlled release depot formulations |
US20050048099A1 (en) * | 2003-01-09 | 2005-03-03 | Allergan, Inc. | Ocular implant made by a double extrusion process |
PT1660057E (pt) | 2003-08-27 | 2012-08-02 | Ophthotech Corp | Terapia de associação para o tratamento de distúrbios neovasculares oculares |
US20050282233A1 (en) * | 2004-03-05 | 2005-12-22 | Ludwig Institute For Cancer Research | Multivalent antibody materials and methods for VEGF/PDGF family of growth factors |
US8685435B2 (en) | 2004-04-30 | 2014-04-01 | Allergan, Inc. | Extended release biodegradable ocular implants |
US20070059336A1 (en) | 2004-04-30 | 2007-03-15 | Allergan, Inc. | Anti-angiogenic sustained release intraocular implants and related methods |
US8591885B2 (en) * | 2004-04-30 | 2013-11-26 | Allergan, Inc. | Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems |
US20060182783A1 (en) | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Sustained release intraocular drug delivery systems |
US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
US20050244472A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Intraocular drug delivery systems containing excipients with reduced toxicity and related methods |
JP4595408B2 (ja) | 2004-07-08 | 2010-12-08 | パナソニック株式会社 | 圧縮機 |
US20060020044A1 (en) | 2004-07-26 | 2006-01-26 | Roger Berlin | Methods and compositions for treating or preventing macular-degeneration related disorders |
CA2582374A1 (en) | 2004-10-04 | 2006-04-20 | Qlt Usa, Inc. | Ocular delivery of polymeric delivery formulations |
US7931909B2 (en) | 2005-05-10 | 2011-04-26 | Allergan, Inc. | Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates |
US20070178138A1 (en) | 2006-02-01 | 2007-08-02 | Allergan, Inc. | Biodegradable non-opthalmic implants and related methods |
US8586556B2 (en) * | 2006-11-03 | 2013-11-19 | Allergan, Inc. | Methods, compositions and drug delivery systems for intraocular delivery of siRNA molecules |
US8039010B2 (en) | 2006-11-03 | 2011-10-18 | Allergan, Inc. | Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier |
US11078262B2 (en) | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
US8231892B2 (en) * | 2007-05-24 | 2012-07-31 | Allergan, Inc. | Biodegradable drug delivery system |
US8080562B2 (en) * | 2008-04-15 | 2011-12-20 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
US20090258924A1 (en) | 2008-04-15 | 2009-10-15 | Allergan, Inc. | METHODS, COMPOSITIONS AND DRUG DELIVERY SYSTEMS FOR INTRAOCULAR DELIVERY OF siRNA MOLECULES |
US8821870B2 (en) | 2008-07-18 | 2014-09-02 | Allergan, Inc. | Method for treating atrophic age related macular degeneration |
JP2012515603A (ja) * | 2009-01-27 | 2012-07-12 | サイレンシード リミテッド | インプラント送達の方法とシステム |
WO2011041642A1 (en) * | 2009-10-01 | 2011-04-07 | Surmodics Pharmaceuticals, Inc. | Microparticle compositions and methods for treating age-related macular degeneration |
AU2011292149A1 (en) | 2010-08-17 | 2013-03-14 | Allergan, Inc. | Method of stabilizing and sterilizing peptides or proteins |
-
2013
- 2013-09-26 TW TW102134859A patent/TWI663985B/zh active
- 2013-09-26 KR KR1020207015606A patent/KR20200065106A/ko not_active Application Discontinuation
- 2013-09-26 JP JP2015534634A patent/JP6317748B2/ja active Active
- 2013-09-26 EP EP13779655.3A patent/EP2900250B1/en active Active
- 2013-09-26 ES ES13779655T patent/ES2709351T3/es active Active
- 2013-09-26 CN CN201380061593.6A patent/CN104812397A/zh active Pending
- 2013-09-26 WO PCT/US2013/061803 patent/WO2014052518A1/en active Application Filing
- 2013-09-26 KR KR1020157010901A patent/KR20150058510A/ko active IP Right Grant
- 2013-09-26 CA CA2886081A patent/CA2886081A1/en not_active Abandoned
- 2013-09-26 BR BR112015006929A patent/BR112015006929A2/pt not_active IP Right Cessation
- 2013-09-26 RU RU2015115358A patent/RU2676102C2/ru active
- 2013-09-26 AU AU2013323553A patent/AU2013323553B2/en active Active
- 2013-09-26 US US14/037,528 patent/US10653621B2/en active Active
-
2016
- 2016-02-05 HK HK16101450.3A patent/HK1213480A1/zh unknown
-
2018
- 2018-10-11 AU AU2018247260A patent/AU2018247260B2/en not_active Ceased
-
2020
- 2020-05-07 US US16/869,237 patent/US20200261358A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN104812397A (zh) | 2015-07-29 |
EP2900250A1 (en) | 2015-08-05 |
TW201417831A (zh) | 2014-05-16 |
ES2709351T3 (es) | 2019-04-16 |
AU2018247260A1 (en) | 2018-11-01 |
KR20200065106A (ko) | 2020-06-08 |
RU2015115358A (ru) | 2016-11-20 |
JP6317748B2 (ja) | 2018-04-25 |
US20140086974A1 (en) | 2014-03-27 |
KR20150058510A (ko) | 2015-05-28 |
BR112015006929A2 (pt) | 2017-07-04 |
US10653621B2 (en) | 2020-05-19 |
RU2676102C2 (ru) | 2018-12-26 |
JP2015532284A (ja) | 2015-11-09 |
US20200261358A1 (en) | 2020-08-20 |
TWI663985B (zh) | 2019-07-01 |
WO2014052518A1 (en) | 2014-04-03 |
AU2013323553B2 (en) | 2018-07-12 |
AU2018247260B2 (en) | 2020-09-17 |
EP2900250B1 (en) | 2018-11-07 |
CA2886081A1 (en) | 2014-04-03 |
AU2013323553A1 (en) | 2015-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1213480A1 (zh) | 用於持續釋放蛋白質的生物可降解的藥物遞送系統 | |
HK1208374A1 (zh) | 用於疏水組合物的生物可降解藥物遞送 | |
HK1205928A1 (zh) | 種眼部給藥系統 | |
HK1206634A1 (zh) | 用於控制釋放不同藥物成分的媒介物 | |
BR112013018828A2 (pt) | sistemas de distribuição de droga | |
IL245544A0 (en) | drug delivery system | |
ZA201502352B (en) | Liposomal drug delivery system | |
HK1205010A1 (zh) | 用於遞送藥物的系統 | |
PL2654864T3 (pl) | System dostarczania leku | |
SG10201701773UA (en) | Hyaluronic Acid-Based Drug Delivery Systems | |
HK1202418A1 (zh) | 用於生物活性試劑的緩釋的藥物遞送系統 | |
EP2630971B8 (en) | Combinations of albumin-based drug delivery systems | |
EP2849770A4 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE DISPOSAL OF ESSENTIALLY WATER-INSOLICED MEDICINAL PRODUCTS | |
ZA201207900B (en) | Fast dissolving drug delivery systems | |
EP2818140A4 (en) | STENT DELIVERY SYSTEM | |
EP2968162A4 (en) | Multi-stage biodegradable drug delivery platform | |
EP2682075A4 (en) | STENT PLACEMENT SYSTEM | |
EP2921152A4 (en) | DRUG DELIVERY SYSTEM | |
HK1204258A1 (zh) | 配藥系統 | |
EP2689753A4 (en) | STENT DELIVERY SYSTEM | |
ZA201309156B (en) | Drug delivery system | |
IL227352A0 (en) | A system for ocular administration of a drug | |
EP2679202A4 (en) | STENT PLACEMENT SYSTEM | |
IL236757B (en) | A device for administering a drug with retention in the digestive tract | |
EP2717802A4 (en) | RECOVERABLE STENT DISPENSING SYSTEM |